Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05474378 · ClinicalTrials.gov registry record · Phase 1
B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme
A Phase 1 study of Brain and Nervous System, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT05474378 is a Phase 1 study of Brain and Nervous System that is actively recruiting participants, run by Stanford University. The registered enrollment target is 39 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05474378, a Phase 1 study of Brain and Nervous System, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open label, non-randomized, single site Phase I study to test the manufacturing feasibility and safety of locoregional (LR) administration of B7-H3CART into the central nervous system of adult subjects with recurrent IDH wild-type GBM using a standard 3+3 dose escalation design.
Conditions Studied
Interventions
- DRUG B7-H3CART
Study Locations (1)
California
- Stanford Cancer Institute - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2022-07-12 |
| Est. Completion | 2026-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05474378
The ClinicalTrials.gov registry entry for NCT05474378 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain and Nervous System appearing as the primary indexed condition, and to 1 intervention - of which B7-H3CART is the first listed.
NCT05474378 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05474378 about?
NCT05474378 is a clinical study titled "B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme". This is an open label, non-randomized, single site Phase I study to test the manufacturing feasibility and safety of locoregional (LR) administration of B7-H3CART into the central nervous system of adult subjects with recurrent IDH wild-type GBM using a standard 3+3 dose escalation design.
What is the current status of trial NCT05474378?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2022-07-12. Estimated completion is 2026-08.
What conditions does trial NCT05474378 study?
This clinical trial studies the following conditions: Brain and Nervous System.
What interventions are being tested in trial NCT05474378?
The interventions under investigation include: B7-H3CART (DRUG).
Who is sponsoring clinical trial NCT05474378?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05474378 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain and Nervous System
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.